Pfizer announced Tuesday that its COVID-19 pill, Paxlovid, is effective against the omicron variant.
The company said three separate lab studies showed the main protease inhibitor in the drug, nirmatrelvir, maintains its effectiveness against the omicron variant.
As reported by The Hill, patients take two tablets of nirmatrelvir with one tablet of another antiviral, ritonavir, twice a day for five days.
“These data suggest that our oral COVID-19 therapy can be an important and effective tool in our continued battle against this devastating virus and current variants of concern, including the highly transmissible Omicron,” Pfizer’s chief scientific officer Mikael Dolsten said. “We will continue to monitor the treatment’s activity in real-world settings and believe that these in vitro findings will continue to be validated.”
As previously reported by Human Events News, the FDA in December authorized the Pfizer pill for emergency use.
Paxlovid will be prescribed for use in adults and children over the age of 12 with mild to moderate sickness who are at risk for severe disease or hospitalization.